Delaney Stratton, PhD
Family · Tucson, AZNPI 1649837618
Payments from drug & device makers
Across 42 payments — averaging $68.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$753
- Regeneron Healthcare Solutions, Inc.$411
- Johnson & Johnson$247
- Teva Pharmaceuticals USA, Inc.$237
- Novartis$153
- UCB, Inc.$150
- plus $909 from 10 others
Across 11 payments — averaging $218.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2K
What the payments were for
- Food & beverage$2,859100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 14 | $753 |
| Regeneron Healthcare Solutions, Inc. | 7 | $411 |
| Johnson & Johnson | 2 | $247 |
| Teva Pharmaceuticals USA, Inc. | 2 | $237 |
| Novartis | 2 | $153 |
| UCB, Inc. | 2 | $150 |
| Genentech USA, Inc. | 1 | $125 |
| AbbVie | 1 | $117 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $114 |
| LEO Pharma Inc. | 1 | $100 |
| TG Therapeutics, Inc. | 1 | $99 |
| Abbott | 1 | $90 |
| Dermavant Sciences, Inc. | 1 | $85 |
| Sun Pharmaceutical Industries Inc. | 3 | $70 |
| Kyowa Kirin, Inc. | 1 | $61 |
| Jazz Pharmaceuticals Inc. | 2 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,859 in reported general payments places this provider in the 85th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValchlorMechlorethamine Hcl | 12 | $71,179 |
| Dupixent PenDupilumab | 11 | $41,304 |
| Fluorouracil | 37 | $2,921 |
| Ketoconazole | 43 | $955 |
| Doxycycline Hyclate | 32 | $924 |
| Metronidazole | 11 | $658 |
| Clindamycin Phosphate | 15 | $542 |
| Triamcinolone Acetonide | 46 | $539 |
| Spironolactone | 15 | $258 |
| Imiquimod | 11 | $242 |
Paid to pharmacies, not to this prescriber.
Other family in Tucson
- Lindsay CarterTucson$108K
- Vicki McIntyreTucson$68K
- Amber KemnitzTucson$33K
- Joy BaynesTucson$30K
- Cynthia CarstenTucson$27K
- Sharon MorganTucson$22K
- Margaret SpencerTucson$19K
- Polina SamoylovaTucson$18K
- Stephanie Niemi-OlsonTucson$15K
- Cindy ChangTucson$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.